Cargando…

t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells

Trastuzumab has led to improved survival rates of HER2(+) breast cancer patients. However, acquired resistance remains a problem in the majority of cases. t-Darpp is over-expressed in trastuzumab-resistant cell lines and its over-expression is sufficient for conferring the resistance phenotype. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denny, Erin C., Kane, Susan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488293/ https://www.ncbi.nlm.nih.gov/pubmed/26121470 http://dx.doi.org/10.1371/journal.pone.0132267

Ejemplares similares

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Darpp-32 and t-Darpp are differentially expressed in normal and malignant mouse mammary tissue
por: Christenson, Jessica L, et al.
Publicado: (2014)

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance
por: Gu, Long, et al.
Publicado: (2009)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

t‐Darpp is an elongated monomer that binds calcium and is phosphorylated by cyclin‐dependent kinases 1 and 5
por: Momand, Jamil, et al.
Publicado: (2017)

DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration
por: Alam, Sk. Kayum, et al.
Publicado: (2018)

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
por: Alam, Sk. Kayum, et al.
Publicado: (2021)

DARPP-32: from neurotransmission to cancer
por: Belkhiri, Abbes, et al.
Publicado: (2016)

The involvement of DARPP-32 in the pathophysiology of schizophrenia
por: Wang, Haitao, et al.
Publicado: (2017)

Spatial Distribution of DARPP-32 in Dendritic Spines
por: Blom, Hans, et al.
Publicado: (2013)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation
por: Alam, Sk. Kayum, et al.
Publicado: (2020)

t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer
por: Vangamudi, Bhavatarini, et al.
Publicado: (2010)

DARPP-32, Jack of All Trades… Master of Which?
por: Yger, Marion, et al.
Publicado: (2011)

Loss of DARPP-32 and calbindin in multiple system atrophy
por: Hayakawa, Hideki, et al.
Publicado: (2013)

Calpain-mediated cleavage of DARPP-32 in Alzheimer’s disease
por: Cho, Kwangmin, et al.
Publicado: (2015)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Activation of IGF1R by DARPP-32 promotes STAT3 signaling in gastric cancer cells
por: Zhu, Shoumin, et al.
Publicado: (2019)

Transient Calcium and Dopamine Increase PKA Activity and DARPP-32 Phosphorylation
por: Lindskog, Maria, et al.
Publicado: (2006)

Influence of DARPP-32 genetic variation on BOLD activation to happy faces
por: Persson, Ninni, et al.
Publicado: (2017)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways
por: Saidy, Behnaz, et al.
Publicado: (2023)

DARPP-32 Is a Robust Integrator of Dopamine and Glutamate Signals
por: Fernandez, Éric, et al.
Publicado: (2006)

Regulation of β-catenin by t-DARPP in upper gastrointestinal cancer cells
por: Vangamudi, Bhavatarini, et al.
Publicado: (2011)

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2
por: Balbuena-Rebolledo, Irving, et al.
Publicado: (2021)

Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
por: You, Daeun, et al.
Publicado: (2023)

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
por: Kane, Aidan, et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Sucrose Abstinence and Environmental Enrichment Effects on Mesocorticolimbic DARPP32 in Rats
por: Grimm, Jeffrey W., et al.
Publicado: (2018)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

PP1, PKA and DARPP‐32 in breast cancer: A retrospective assessment of protein and mRNA expression
por: Saidy, Behnaz, et al.
Publicado: (2021)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
por: Baker, Andrew T., et al.
Publicado: (2014)

EGFR Expression in HER2-Driven Breast Cancer Cells
por: Weinberg, Florian, et al.
Publicado: (2020)

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells
por: Ferreira, Renan B., et al.
Publicado: (2017)

Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells
por: Dietel, Eric, et al.
Publicado: (2018)

Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns
por: Carratalá-Ros, Carla, et al.
Publicado: (2021)

AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
por: Jhaveri, Teraneh Z., et al.
Publicado: (2015)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ptvkujhblttvs55mmuabjsj9d